This site is intended for Healthcare professionals only.

Albumin administration may prolong survival in cirrhosis


Albumin administration may prolong survival in cirrhosis
Long-term administration of human albumin (HA) prolongs overall survival in patients with decompensated cirrhosis, finds a new study published in the journal The Lancet. 
Paolo Caraceni, Department of Medical and Surgical Sciences, and Center for Applied Biomedical Research, University of Bologna, Bologna, Italy, and colleagues designed The human Albumin for the treatmeNt of aScites in patients With hEpatic ciRrhosis (ANSWER) study to collect the evidence on the efficacy of long-term HA administration in patients with decompensated cirrhosis.
For the study, the researchers conducted an investigator-initiated multicentre randomized, parallel, open-label, pragmatic trial in 33 academic and non-academic Italian hospitals. Patients with cirrhosis and uncomplicated ascites who were treated with anti-aldosteronic drugs (≥200 mg/day) and furosemide (≥25 mg/day) to receive either standard medical treatment (SMT) or SMT plus HA (40 g twice weekly for 2 weeks, and then 40 g weekly) for up to 18 months.
The primary endpoint was 18-month mortality, evaluated as a difference of events and analysis of survival time in patients included in the modified intention-to-treat and per-protocol populations.
From April 2, 2011, to May 27, 2015, 440 patients were randomly assigned and 431 were included in the modified intention-to-treat analysis.
Key Findings:
  • 38 of 218 patients died in the SMT plus HA group and 46 of 213 in the SMT group.
  • Overall 18-month survival was significantly higher in the SMT plus HA than in the SMT group (Kaplan-Meier estimates 77% vs 66%; p=0·028), resulting in a 38% reduction in the mortality hazard ratio (0·62 [95% CI 0·40–0·95]).
  • 46 (22%) patients in the SMT group and 49 (22%) in the SMT plus HA group had grade 3–4 non-liver related adverse events.
“In this trial, long-term HA administration prolongs overall survival and might act as a disease-modifying treatment in patients with decompensated cirrhosis,” concluded the authors.
For more information log on to https://doi.org/10.1016/S0140-6736(18)30840-7

The following two tabs change content below.
Medha Baranwal

Medha Baranwal

Medha Baranwal joined Medical Dialogues as a Desk Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She can be contacted at medha@medicaldialogues.in. Contact no. 011-43720751
Source: With inputs from The Lancet

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted